Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176

1.

Prophylactic bypassing agent use before and during immune tolerance induction in patients with haemophilia A and inhibitors to FVIII.

Carpenter SL, Khair K, Gringeri A, Valentino LA.

Haemophilia. 2018 Jul;24(4):570-577. doi: 10.1111/hae.13534. Epub 2018 Jun 14. Review.

PMID:
29901839
2.

The multiple benefits of sport in haemophilia.

Farrugia A, Gringeri A, von Mackensen S.

Haemophilia. 2018 May;24(3):341-343. doi: 10.1111/hae.13496. Epub 2018 May 6. No abstract available.

3.

Comparative analysis of marketed factor VIII products: recombinant products are not alike vis-a-vis soluble protein aggregates and subvisible particles.

Anzengruber J, Lubich C, Prenninger T, Gringeri A, Scheiflinger F, Reipert BM, Malisauskas M.

J Thromb Haemost. 2018 Jun;16(6):1176-1181. doi: 10.1111/jth.14125. Epub 2018 May 11.

PMID:
29665242
4.

Thromboembolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published data.

Rota M, Cortesi PA, Crea R, Gringeri A, Mantovani LG.

Blood Adv. 2017 Dec 12;1(26):2637-2642. doi: 10.1182/bloodadvances.2017011536. eCollection 2017 Dec 12.

5.

Pattern of bleeding in a large prospective cohort of haemophilia A patients: A three-year follow-up of the AHEAD (Advate in HaEmophilia A outcome Database) study.

Khair K, Mazzucconi MG, Parra R, Santagostino E, Tsakiris DA, Hermans C, Oldenburg J, Spotts G, Steinitz-Trost K, Gringeri A.

Haemophilia. 2018 Jan;24(1):85-96. doi: 10.1111/hae.13361. Epub 2017 Oct 17.

PMID:
29044825
6.

Meta-analysis on incidence of inhibitors in patients with haemophilia A treated with recombinant factor VIII products.

Rota M, Cortesi PA, Steinitz-Trost KN, Reininger AJ, Gringeri A, Mantovani LG.

Blood Coagul Fibrinolysis. 2017 Dec;28(8):627-637. doi: 10.1097/MBC.0000000000000647.

PMID:
28678027
7.

Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement.

Iorio A, Iserman E, Blanchette V, Dolan G, Escuriola Ettingshausen C, Hermans C, Negrier C, Oldenburg J, Reininger A, Rodriguez-Merchan C, Spannagl M, Valentino LA, Young G, Steinitz-Trost KN, Gringeri A.

Haemophilia. 2017 May;23(3):e170-e179. doi: 10.1111/hae.13215. Epub 2017 Mar 26.

PMID:
28345268
8.

Cost-effectiveness analysis of pharmacokinetic-driven prophylaxis vs. standard prophylaxis in patients with severe haemophilia A.

Iannazzo S, Cortesi PA, Crea R, Steinitz K, Mantovani LG, Gringeri A.

Blood Coagul Fibrinolysis. 2017 Sep;28(6):425-430. doi: 10.1097/MBC.0000000000000610.

PMID:
27898515
9.

An innovative outcome-based care and procurement model of hemophilia management.

Gringeri A, Doralt J, Valentino LA, Crea R, Reininger AJ.

Expert Rev Pharmacoecon Outcomes Res. 2016 Jun;16(3):337-45. doi: 10.1080/14737167.2016.1178066. Epub 2016 May 3.

PMID:
27074697
10.

Global Post-Authorization Safety Surveillance Study: real-world data on prophylaxis and on-demand treatment using FEIBA (an activated prothrombin complex concentrate).

Negrier C, Voisin S, Baghaei F, Numerof R, Novack A, Doralt JE, Romanov V, Gringeri A; FEIBA PASS Study group.

Blood Coagul Fibrinolysis. 2016 Jul;27(5):551-6. doi: 10.1097/MBC.0000000000000525.

11.

Health-related quality of life assessment in haemophilia patients on prophylaxis therapy: a systematic review of results from prospective clinical trials.

Oladapo AO, Epstein JD, Williams E, Ito D, Gringeri A, Valentino LA.

Haemophilia. 2015 Sep;21(5):e344-58. doi: 10.1111/hae.12759. Epub 2015 Jul 17. Review.

PMID:
26390060
12.

Immune tolerance induction in patients with haemophilia a and inhibitors: effectiveness and cost analysis in an European Cohort (The ITER Study).

Rocino A, Cortesi PA, Scalone L, Mantovani LG, Crea R, Gringeri A; European Haemophilia Therapy Strategy Board (EHTSB); European Haemophilia Therapy Strategy Board EHTSB.

Haemophilia. 2016 Jan;22(1):96-102. doi: 10.1111/hae.12780. Epub 2015 Aug 17.

PMID:
26278414
13.

Correction: Santos, R.S., et al. Improvement of IFNγ ELISPOT Performance Following Overnight Resting of Frozen PBMC Samples Confirmed Through Rigorous Statistical Analysis. Cells 2015, 4, 1-18.

Santos R, Buying A, Sabri N, Yu J, Gringeri A, Bender J, Janetzki S, Pinilla C, Judkowski VA.

Cells. 2015 Apr 21;4(2):133-4. doi: 10.3390/cells4020133.

14.

Recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis--new insight provided by pharmacokinetic modelling.

Gringeri A, Wolfsegger M, Steinitz KN, Reininger AJ.

Haemophilia. 2015 May;21(3):300-6. doi: 10.1111/hae.12605. Epub 2015 Jan 21.

PMID:
25643824
15.

Individualizing prophylaxis in hemophilia: a review.

Petrini P, Valentino LA, Gringeri A, Re WM, Ewenstein B.

Expert Rev Hematol. 2015 Apr;8(2):237-46. doi: 10.1586/17474086.2015.1002465. Epub 2015 Jan 20. Review.

PMID:
25600578
16.

Improvement of IFNg ELISPOT Performance Following Overnight Resting of Frozen PBMC Samples Confirmed Through Rigorous Statistical Analysis.

Santos R, Buying A, Sabri N, Yu J, Gringeri A, Bender J, Janetzki S, Pinilla C, Judkowski VA.

Cells. 2014 Dec 24;4(1):1-18. doi: 10.3390/cells4010001. Erratum in: Cells. 2015;4(2):133-4.

17.

The burden of bleeding in haemophilia: is one bleed too many?

Gringeri A, Ewenstein B, Reininger A.

Haemophilia. 2014 Jul;20(4):459-63. doi: 10.1111/hae.12375. Epub 2014 Jan 29. Review.

PMID:
24472015
18.

Development of novel treatment options for patients with haemophilia.

Ehrlich HJ, Wong WY, Ewenstein BM, Dockal M, Turecek PL, Gringeri A, Chehadeh H, Löw-Baselli A, Scheiflinger F, Reininger AJ.

Hamostaseologie. 2013;33 Suppl 1:S36-8. Review.

PMID:
24169902
19.

Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study.

Gringeri A, Leissinger C, Cortesi PA, Jo H, Fusco F, Riva S, Antmen B, Berntorp E, Biasoli C, Carpenter S, Kavakli K, Morfini M, Négrier C, Rocino A, Schramm W, Windyga J, Zülfikar B, Mantovani LG.

Haemophilia. 2013 Sep;19(5):736-43. doi: 10.1111/hae.12178. Epub 2013 Jun 4.

PMID:
23731246
20.

A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A.

Lane J, McLaren PJ, Dorrell L, Shianna KV, Stemke A, Pelak K, Moore S, Oldenburg J, Alvarez-Roman MT, Angelillo-Scherrer A, Boehlen F, Bolton-Maggs PH, Brand B, Brown D, Chiang E, Cid-Haro AR, Clotet B, Collins P, Colombo S, Dalmau J, Fogarty P, Giangrande P, Gringeri A, Iyer R, Katsarou O, Kempton C, Kuriakose P, Lin J, Makris M, Manco-Johnson M, Tsakiris DA, Martinez-Picado J, Mauser-Bunschoten E, Neff A, Oka S, Oyesiku L, Parra R, Peter-Salonen K, Powell J, Recht M, Shapiro A, Stine K, Talks K, Telenti A, Wilde J, Yee TT, Wolinsky SM, Martinson J, Hussain SK, Bream JH, Jacobson LP, Carrington M, Goedert JJ, Haynes BF, McMichael AJ, Goldstein DB, Fellay J; NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI).

Hum Mol Genet. 2013 May 1;22(9):1903-10. doi: 10.1093/hmg/ddt033. Epub 2013 Jan 30.

21.

How I treat inhibitors in haemophilia.

Makris M, Hay CR, Gringeri A, D'Oiron R.

Haemophilia. 2012 Jul;18 Suppl 4:48-53. doi: 10.1111/j.1365-2516.2012.02829.x.

PMID:
22726083
22.

Management of bleeding disorders in children.

Berntorp E, Halimeh S, Gringeri A, Mathias M, Escuriola C, Pérez R.

Haemophilia. 2012 May;18 Suppl 2:15-23. doi: 10.1111/j.1365-2516.2012.02796.x. Review.

PMID:
22530575
23.

Haemophilia care in Europe: the ESCHQoL study.

Schramm W, Gringeri A, Ljung R, Berger K, Crispin A, Bullinger M, Giangrande PL, Von Mackensen S, Mantovani LG, Nemes L, Serban M; ESCHQOL Study Group.

Haemophilia. 2012 Sep;18(5):729-37. doi: 10.1111/j.1365-2516.2012.02847.x. Epub 2012 May 29.

PMID:
22639833
24.

Tertiary prophylaxis in adults: is there a rationale?

Gringeri A, Lambert T, Street A, Aledort L; Adolescent/Adult Prophylaxis Expert Working Group of the International Prophylaxis Study Group.

Haemophilia. 2012 Sep;18(5):722-8. doi: 10.1111/j.1365-2516.2012.02843.x. Epub 2012 May 29. Review.

PMID:
22639786
25.

Continuous infusion in haemophilia: current practice in Europe.

Batorova A, Holme P, Gringeri A, Richards M, Hermans C, Altisent C, Lopez-Fernández M, Fijnvandraat K; European Haemophilia Treatment Standardisation Board.

Haemophilia. 2012 Sep;18(5):753-9. doi: 10.1111/j.1365-2516.2012.02810.x. Epub 2012 Apr 25.

PMID:
22530687
26.

Pain management in patients with haemophilia: a European survey.

Holstein K, Klamroth R, Richards M, Carvalho M, Pérez-Garrido R, Gringeri A; European Haemophilia Therapy Standardization Board.

Haemophilia. 2012 Sep;18(5):743-52. doi: 10.1111/j.1365-2516.2012.02808.x. Epub 2012 Apr 25. Review.

PMID:
22530627
27.

Haemophilia prophylaxis: how can we justify the costs?

Feldman BM, Berger K, Bohn R, Carcao M, Fischer K, Gringeri A, Hoots K, Mantovani L, Willan AR, Schramm W.

Haemophilia. 2012 Sep;18(5):680-4. doi: 10.1111/j.1365-2516.2012.02790.x. Epub 2012 Apr 17. Review.

PMID:
22507524
28.

Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors.

Leissinger C, Gringeri A, Antmen B, Berntorp E, Biasoli C, Carpenter S, Cortesi P, Jo H, Kavakli K, Lassila R, Morfini M, Négrier C, Rocino A, Schramm W, Serban M, Uscatescu MV, Windyga J, Zülfikar B, Mantovani L.

N Engl J Med. 2011 Nov 3;365(18):1684-92. doi: 10.1056/NEJMoa1104435. Erratum in: N Engl J Med. 2011 Dec 22;365(25):2441.

29.

Factor VIII inhibitor and source of replacement therapy.

Mannucci PM, Gringeri A, Santagostino E, Peyvandi F.

Blood Transfus. 2012 Jan;10(1):112-3. doi: 10.2450/2011.0064-11. Epub 2011 Sep 21. No abstract available.

30.

Ultrasonography of haemophilic arthropathy.

Muça-Perja M, Riva S, Grochowska B, Mangiafico L, Mago D, Gringeri A.

Haemophilia. 2012 May;18(3):364-8. doi: 10.1111/j.1365-2516.2011.02672.x. Epub 2011 Oct 17.

PMID:
21999202
31.

Understanding FVIII/VWF complex--report from a symposium of XXIX WFH meeting 2010.

Gringeri A, Ofosu FA, Grancha S, Oldenburg J, Ewing NP, Federici AB.

Haemophilia. 2012 May;18(3):469-75. doi: 10.1111/j.1365-2516.2011.02655.x. Epub 2011 Sep 22.

PMID:
21943193
32.

Health-related quality of life and psychological well-being in elderly patients with haemophilia.

von Mackensen S, Gringeri A, Siboni SM, Mannucci PM; Italian Association Of Haemophilia Centres (AICE).

Haemophilia. 2012 May;18(3):345-52. doi: 10.1111/j.1365-2516.2011.02643.x. Epub 2011 Sep 12.

PMID:
21910788
33.

Safety and effectiveness of raltegravir in patients with haemophilia and anti-HIV multidrug resistance.

Mangiafico L, Perja M, Fusco F, Riva S, Mago D, Gringeri A.

Haemophilia. 2012 Jan;18(1):108-11. doi: 10.1111/j.1365-2516.2011.02610.x. Epub 2011 Jul 18.

PMID:
21762404
34.

Consumption of clotting factors in severe haemophilia patients undergoing prophylaxis and on-demand treatment in Italy.

Giampaolo A, Abbonizio F, Puopolo M, Arcieri R, Mannucci PM; Italian Association of Haemophilia Centres, Hassan HJ, Accorsi A, Ettorre PC, Schiavoni M, Palareti G, Rodorigo G, Valdré L, Amaddii G, Billio A, Notarangelo L, Iannacaro P, Muleo P, Biasioli C, Rossi V, Alatri A, Testa S, Vincenzi D, Scapoli G, Morfini M, Molinari AC, Lapecorella M, Mariani G, Baudo F, Caimi MT, Federici AB, Gringeri A, Mannucci PM, Santagostino E, Marietta M, Coppola A, Di Minno G, Perricone C, Schiavulli M, Miraglia E, Rocino A, Zanon E, Gagliano F, Mancuso G, Siragusa S, Rivolta F, Tagliaferri A, Gamba G, Iorio A, Oliovecchio E, Dragani A, Arbasi MC, Albertini P, Mancino A, Lombardo VT, Latella C, D'Incà M, Landolfi Raffaele, Biondo Francesca, Mazzucconi MG, Santoro Cristina, Mameli AL, Piseddu G, Schinco PC, Messina M, Rossetti G, Barillari G, Feola G, Franchini M, Gandini G, Castaman G, Rodeghiero F.

Transfus Med. 2011 Aug;21(4):280-4. doi: 10.1111/j.1365-3148.2011.01074.x. Epub 2011 Mar 30. No abstract available.

PMID:
21733006
35.

Modeling costs and outcomes associated with a treatment algorithm for problem bleeding episodes in patients with severe hemophilia a and high-titer inhibitors.

Bonnet P, Gringeri A, Gomperts E, Leissinger CA, d'Oiron R, Teitel J, Young G, Franklin M, Ewenstein B, Berntorp E.

Am Health Drug Benefits. 2011 Jul;4(4):219-31.

36.

Pharmacotherapy of haemophilia A.

Gringeri A, Muça-Perja M, Mangiafico L, von Mackensen S.

Expert Opin Biol Ther. 2011 Aug;11(8):1039-53. doi: 10.1517/14712598.2011.570006. Epub 2011 Jun 20. Review.

PMID:
21682657
37.

Factor VIII safety: plasma-derived versus recombinant products.

Gringeri A.

Blood Transfus. 2011 Oct;9(4):366-70. doi: 10.2450/2011.0092-10. Epub 2011 Apr 12. Review. No abstract available.

38.

A consensus statement on clinical trials of bypassing agent prophylaxis in inhibitor patients.

Teitel J, Berntorp E, Dolan G, Fischer K, Gringeri A, Kessler C, Lambert T, Leissinger C, Nemes L, Shima M.

Haemophilia. 2011 May;17(3):516-21. doi: 10.1111/j.1365-2516.2010.02440.x. Epub 2011 Mar 3.

PMID:
21371181
39.

Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors.

Gringeri A, Fischer K, Karafoulidou A, Klamroth R, López-Fernández MF, Mancuso E; European Haemophilia Treatment Standardisation Board (EHTSB).

Haemophilia. 2011 Jul;17(4):630-5. doi: 10.1111/j.1365-2516.2010.02467.x. Epub 2011 Feb 15.

PMID:
21323801
40.

A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study).

Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM; ESPRIT Study Group.

J Thromb Haemost. 2011 Apr;9(4):700-10. doi: 10.1111/j.1538-7836.2011.04214.x.

41.

Identifying non-responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition.

Berntorp E, Collins P, D'Oiron R, Ewing N, Gringeri A, Négrier C, Young G.

Haemophilia. 2011 Jan;17(1):e202-10. doi: 10.1111/j.1365-2516.2010.02377.x. Epub 2010 Sep 2.

PMID:
20825500
42.

Special lectures in haemophilia management.

Batorova A, High KA, Gringeri A.

Haemophilia. 2010 Jul;16 Suppl 5:22-8. doi: 10.1111/j.1365-2516.2010.02289.x. Review.

PMID:
20590852
43.

Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report.

Astermark J, Altisent C, Batorova A, Diniz MJ, Gringeri A, Holme PA, Karafoulidou A, Lopez-Fernández MF, Reipert BM, Rocino A, Schiavoni M, von Depka M, Windyga J, Fijnvandraat K; European Haemophilia Therapy Standardisation Board.

Haemophilia. 2010 Sep 1;16(5):747-66. doi: 10.1111/j.1365-2516.2010.02231.x. Epub 2010 Apr 14. Review.

PMID:
20398077
44.

Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review.

Iorio A, Halimeh S, Holzhauer S, Goldenberg N, Marchesini E, Marcucci M, Young G, Bidlingmaier C, Brandao LR, Ettingshausen CE, Gringeri A, Kenet G, Knöfler R, Kreuz W, Kurnik K, Manner D, Santagostino E, Mannucci PM, Nowak-Göttl U.

J Thromb Haemost. 2010 Jun;8(6):1256-65. doi: 10.1111/j.1538-7836.2010.03823.x. Epub 2010 Mar 17. Review.

45.

Bypassing agent regimens and costs for prophylaxis in patients with inhibitors.

Gringeri A.

Haemophilia. 2009 Nov;15(6):1336-7. doi: 10.1111/j.1365-2516.2009.02068.x. Epub 2009 Jun 24. No abstract available.

PMID:
19558488
46.

Inhibitors in haemophilia A: the role of VWF/FVIII concentrates--a meeting report.

Kaveri S, Gringeri A, Heisel-Kurth M, Kreuz W.

Haemophilia. 2009 Mar;15(2):587-91. No abstract available.

PMID:
19347997
47.
48.

The application of bypassing-agent prophylaxis in haemophilia A patients with inhibitors: a meeting report.

Valentino LA, Carcao M, Mathew P, Leissinger CA, Berntorp E, Blanchette V, Escuriola-Ettingshausen C, Ewenstein B, Ewing N, Gringeri A, Hoots WK, Negrier C.

Haemophilia. 2009 Jul;15(4):959-65. doi: 10.1111/j.1365-2516.2008.01953.x. Epub 2009 Mar 23. No abstract available.

PMID:
19320750
49.

Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy.

Siboni SM, Mannucci PM, Gringeri A, Franchini M, Tagliaferri A, Ferretti M, Tradati FC, Santagostino E, von Mackensen S; Italian Association of Haemophilia Centres (AICE).

J Thromb Haemost. 2009 May;7(5):780-6. doi: 10.1111/j.1538-7836.2009.03318.x. Epub 2009 Feb 12.

50.

Quality of life in haemophilia.

Gringeri A, Von Mackensen S.

Haemophilia. 2008 Jul;14 Suppl 3:19-25. doi: 10.1111/j.1365-2516.2008.01709.x.

PMID:
18510517

Supplemental Content

Loading ...
Support Center